Results 231 to 240 of about 180,170 (299)

Phase IIB, Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID‐19

European Journal of Haematology, EarlyView.
ABSTRACT Introduction Endothelial dysfunction is key in COVID‐19 pathogenesis. This randomized, double‐blind phase IIb trial investigated continuous intravenous infusion of defibrotide in patients hospitalized with SARS‐CoV‐2 infection and respiratory failure.
Ruben Jara Rubio, Antonio José Martinez‐Mellado, Jonathan Kiwitt‐Cárdenas, José G. Clavel, Bartolomé García‐Perez, Pedro Castro, Maribel Diaz‐Ricart, Andrés Carrillo‐Alcaraz, Amparo López‐Bernús, Enrique Bernal Morell, Aychel Roura, Sonia Marín, Francisco‐José Ruiz‐López, Elena Solana‐Martinez, Domingo Martinez‐Baño, Carlos L. Albacete Moreno, Enriqueta Andreu Soler, Adrián Tellez Santoyo, Sara Fernández Méndez, Jose A. Noguera Velasco, Iria Cebreiros Lopez, Andrés Parrilla, Alberto Espuny‐Miró, David García‐Bernal, Miguel Blanquer, Andrés Sánchez‐Salinas, Francisca Iniesta, Cristina Hernandez Garcia, Manuel Muro, Alfredo Minguela Puras, Antonio Moreno‐Docón, Alberto M. Torres‐Cantero, Maria Munoz Garcia, Manuel Serrano, Massimo Iacobelli, Carmelo Carlo‐Stella, Lee‐Jen Wei, Paul G. Richardson, José M. Moraleda   +38 more
wiley   +1 more source

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

European Journal of Haematology, EarlyView.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo, Richard J. Simpson, Emmanuel Katsanis   +2 more
wiley   +1 more source

CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma. [PDF]

Hemasphere
Ferment B, Ouedrani A, Talbot A, Mouri N, Zarnitzky P, Stammler R, Vaugeois T, Diep A, Harel S, Royer B, Theves F, Forgeard N, Allain V, Caillat-Zucman S, Arnulf B.   +14 more
europepmc   +1 more source

Survival After Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Cardiac dysfunction is a major morbidity among survivors of adolescent and young adult (AYA) lymphoma. Although high mortality after cardiovascular disease (CVD) diagnosis has been shown in other cancer survivor populations, this has not been investigated in a diverse population of survivors of AYA lymphoma.
Karan Gowda, Medha Gupta, Adrian Aguilar, Carlos Cruz, Amanda Warner, Elizabeth R. Rodriguez, Sairah Ahmed, Branko Cuglievan, Joel Milam, David R. Freyer, Kimberly A. Miller, Greg Aune, Debra Eshelman‐Kent, Karen Albritton, Efstratios Koutroumpakis, Michael E. Roth, Jian Wang, Michelle A. T. Hildebrandt   +17 more
wiley   +1 more source

Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial. [PDF]

J Patient Rep Outcomes
Mina R, Mylin AK, Yokoyama H, Magen H, Alsdorf W, Shune L, Isufi I, Harrison SJ, Shah UA, De Champlain A, Katz EG, Gries KS, Schecter JM, Lendvai N, Slaughter A, Lonardi C, Deraedt W, Costa Filho O, Patel N, Florendo E, Ho KF, Karlin L, Weisel K.   +22 more
europepmc   +1 more source

Junctional Adhesion Molecule‐A (JAM‐A) Associates With High‐Risk Disease in Multiple Myeloma Patients and a Structure‐Based Rationally‐Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo

European Journal of Haematology, EarlyView.
ABSTRACT Multiple myeloma (MM) is an incurable malignancy of terminally‐differentiated plasma cells that represents a major clinical challenge despite unprecedented therapeutic advances, particularly for patients with cytogenetically‐defined high‐risk MM (HR‐MM).
Niamh McAuley, Roisin McAvera, Dimitri Bong, Lara Donnelly, Izabela Cymer, Marian Brennan, Joanna Fay, Lance Hudson, John Quinn, Siobhan V. Glavey, Ann M. Hopkins   +10 more
wiley   +1 more source

The Art of Deception: Multiple Myeloma Imitating Spondyloarthritis-A Case Report. [PDF]

Clin Case Rep
Khatri P, Subedi A, Dahal B, Shrestha G, Phuyal M, Adhikari R.   +5 more
europepmc   +1 more source

Risk Factors of Blood Culture Positivity and Mortality in Bloodstream Infections: A Population‐Based Study of Patients With B‐Cell Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Background Bloodstream infections remain a major cause of mortality among cancer patients. Pathogen surveillance and risk stratification tools are key to improved management. This study describes trends in causative pathogens and explores risk factors for positive blood cultures (PBCs) and post‐infection mortality in cancer patients.
Mathias Holmsgaard Eskesen, Alexander Djupnes Fuglkjær, Tarec Christoffer El‐Galaly, Paw Jensen, Izabela Ewa Nielsen, Laurids Østergaard Poulsen, Mikkel Runason Simonsen, Kirstine Kobberøe Søgaard   +7 more
wiley   +1 more source

Identification and validation of prognostic genes related to centrosome amplification in multiple myeloma. [PDF]

PeerJ
Liao P, Tan J, Zeng L, Lai P, Wei X.
europepmc   +1 more source

Light Chain Monoclonal Gammopathy of Undetermined Significance: Diagnosis, Biology, and Clinical Management

European Journal of Haematology, EarlyView.
ABSTRACT Light chain monoclonal gammopathy of undetermined significance (LC‐MGUS) is defined by an abnormal serum free light chain ratio and elevated involved light chain in the absence of a detectable immunoglobulin heavy chain on immunofixation and of end‐organ damage attributable to a plasma cell disorder.
Sigurður Yngvi Kristinsson, Thórir Einarsson Long, Sigrún Thorsteinsdóttir   +2 more
wiley   +1 more source